Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA239-0004  |   NCT06875310

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • 157
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA).
    1. Locally advanced or metastatic disease.
      1. Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion.
        1. No prior systemic anti-cancer therapy given for advanced or metastatic disease.
          1. Not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection).
            1. Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter.
              1. Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay, Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx.

                Exclusion Criteria

                Exclusion Criteria Icon
                :
                • Participants with an active autoimmune or inflammatory disease requiring systemic treatment within 2 years.
                  1. Uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment that are ongoing or with risk of recurrence.
                    1. Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities.
                      1. Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry.
                        1. Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting.
                          1. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration.
                            Additional Information *
                            • Other protocol-defined Inclusion/Exclusion criteria apply.

                              Treatment Options

                              Study Arms

                              ASSIGNED INTERVENTION

                              Study Arms

                              Experimental: Adagrasib

                              ASSIGNED INTERVENTION
                              • Drug: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin

                              Study Arms

                              Placebo Comparator: Placebo

                              ASSIGNED INTERVENTION
                              • Drug: Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin
                              Take the first step to see if you Match to a Clinical Trial – Check if you qualify
                              Check if you qualify
                              Answer some questions about Your health to see if you may match to this trial
                              Match to a Trial
                              If you are a match, click on the study to see the list of study site locations
                              Select a Study Site Location
                              Select a study site location that is convenient for you
                              Register
                              Provide your contact details for the study site to connect with you.

                              Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you